A Proteomic Co-Clinical Trial of BGJ-398 in FGFR-Driven Biliary Cancers
Abstract
Intrahepatic cholangiocarcinomas (ICC) is a dead malignancy of the liver bile ducts (<10 5-year survival for patients of all stages) with few therapeutic options for advanced disease. The project involves translational studies relating targeting the Fibroblast Growth Factor Receptor (FGFR) signaling pathway in ICCs harboring alterations in the FGFR pathway. FGFR alterations (most commonly fusions of the FGFR2 gene that result in activation of theFGFR2 kinase) are present in ~20 of ICCs and clinical trials with FGFR kinase inhibitors are showing promise in these patients. However, resistance inevitably arises, limiting therapeutic efficacy. The goals of this project are to understand the basis of FGFR signaling dependency in FGFR-activated ICC, to elucidate mechanisms of clinical acquired resistance, and to improve therapeutic strategies against this subset of patients that improve initial responses and overcome resistance.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2018
- Accession Number
- AD1061925
Entities
People
- Kevan M. Shokat
Organizations
- University of California Regents